What is the likely diagnosis and appropriate treatment for an 88-year-old patient presenting with leukopenia, anemia, low hematocrit, low MCHC, and mildly elevated RDW?

Likely Diagnosis and Treatment for 88-Year-Old with Pancytopenia

This 88-year-old patient with pancytopenia (leukopenia, normocytic anemia with low MCHC, and likely thrombocytopenia) requires immediate bone marrow aspiration and biopsy to exclude myelodysplastic syndrome (MDS), which is the most probable diagnosis given the age and laboratory findings. 1

Immediate Diagnostic Workup

Mandatory bone marrow evaluation must include:

• Bone marrow aspirate with iron stain to assess for ring sideroblasts and dysplasia 2
• Core biopsy to evaluate cellularity, fibrosis, and topography 2
• Cytogenetic analysis to identify chromosomal abnormalities (del 5q, chromosome 7 abnormalities, complex karyotype) 2, 1
• Flow cytometry to detect abnormal immunophenotypes and exclude lymphoproliferative disorders 2, 1
• Blast percentage enumeration in both peripheral blood and bone marrow 2

Additional required laboratory tests before bone marrow:

• Serum erythropoietin level (must be drawn before any RBC transfusion) 2
• Vitamin B12 and RBC folate levels 2
• Iron studies (serum iron, total iron binding capacity, ferritin) 2
• Reticulocyte count 2
• Lactate dehydrogenase, bilirubin, haptoglobin 2
• HIV and hepatitis C testing (mandatory regardless of perceived risk) 1
• Helicobacter pylori testing 1

Interpretation of Current Laboratory Values

The patient's labs suggest normocytic anemia (MCHC 30.8 g/dL is low-normal to slightly low, MCV would need to be calculated but RBC 3.19 suggests normocytic pattern) with leukopenia (WBC 3.3) and mildly elevated RDW (15.5), which is consistent with MDS 2, 3. The combination of cytopenias in an 88-year-old strongly suggests MDS until proven otherwise 1, 4.

Treatment Approach Based on MDS Risk Stratification

If Lower-Risk MDS is Confirmed (IPSS-R very low, low, or intermediate):

For symptomatic anemia (hemoglobin 9.1 g/dL):

1. If serum erythropoietin ≤500 mU/L: Start erythropoiesis-stimulating agents (ESAs) as first-line therapy 2, 5

   • Recombinant EPO 30,000-80,000 units weekly OR darbepoetin 150-300 μg weekly 2
   • Expected response rate: 40-60% when baseline EPO is low 2
   • Assess response after 8-12 weeks 2

2. If serum erythropoietin >500 mU/L or ESA failure:

   • Consider immunosuppressive therapy with anti-thymocyte globulin (ATG) if patient has normal karyotype or trisomy 8, especially with concurrent thrombocytopenia 2
   • Alternative: Azacitidine if approved in your region for lower-risk MDS 2

3. If del(5q) is present: Lenalidomide 10 mg/day for 3 weeks every 4 weeks is preferred, with 60-65% RBC transfusion independence rate 2

For leukopenia with neutropenia:

• G-CSF only during active infections with fever, not for prophylaxis 2, 6
• Broad-spectrum antibiotics immediately for any fever 6

For thrombocytopenia (if platelets are low):

• Platelet transfusions only if <10 × 10⁹/L or <50 × 10⁹/L with active bleeding 2, 1
• Consider thrombopoietin receptor agonists (eltrombopag or romiplostim) if marrow blasts <5%, though 15% risk of transient blast increase requires monitoring 2, 1

If Higher-Risk MDS is Confirmed (IPSS-R intermediate, high, or very high):

At age 88, this patient is considered frail and NOT a candidate for:

• Allogeneic stem cell transplantation 2, 5
• Intensive AML-like chemotherapy 2, 5

Recommended treatment:

• Azacitidine 75 mg/m² subcutaneously for 7 consecutive days every 28 days 2, 6
• Administer at least 6 cycles before assessing response, as most patients respond only after several courses 2, 6

Supportive Care Strategy

RBC transfusion thresholds:

• Maintain hemoglobin ≥8 g/dL, or 9-10 g/dL if cardiovascular disease or poor functional tolerance present 1, 6, 5
• Transfuse sufficient units (over 2-3 days if needed) to increase hemoglobin >10 g/dL to improve quality of life 6, 5

Iron overload monitoring (if transfusion-dependent):

• After 70-80 RBC units (approximately 20-60 concentrates), evaluate for iron overload 1, 5
• Initiate iron chelation when ferritin >1,000 ng/mL with evidence of organ iron deposition 1
• Use cardiac MRI (T2*) to assess cardiac iron loading 1

Critical Pitfalls to Avoid

• Never skip bone marrow examination in patients ≥60 years with unexplained cytopenias—age alone mandates MDS evaluation 1
• Do not omit HIV and hepatitis C testing even in elderly patients, as these infections require distinct management 1
• Do not delay broad-spectrum antibiotics in febrile neutropenic patients 6
• Do not transfuse to arbitrary hemoglobin targets—individualize between 8-10 g/dL based on cardiovascular status and functional capacity 6
• Do not use G-CSF prophylactically for neutropenia, as prolonged use has not demonstrated survival benefit 2, 6
• Do not pursue intensive therapies (allogeneic transplant, intensive chemotherapy) in an 88-year-old frail patient 2, 5

Treatment Priority Algorithm

The primary goal for this 88-year-old patient is symptom management, quality of life improvement, and minimizing treatment-related toxicity 5. Focus on supportive transfusions, treating infections promptly, and considering disease-modifying therapy (ESAs or azacitidine) only after MDS risk stratification is complete 1, 5.